Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group

Brian M. Alexander, Evanthia Galanis, W. K.Alfred Yung, Karla V. Ballman, James M. Boyett, Timothy F. Cloughesy, John F. Degroot, Jason T. Huse, Bhupinder Mann, Warren Mason, Ingo K. Mellinghoff, Tom Mikkelsen, Paul S. Mischel, Brian P. O'Neill, Michael D. Prados, Jann N. Sarkaria, Abdul Tawab-Amiri, Lorenzo Trippa, Xiaobu Ye, Keith L. LigonDonald A. Berry, Patrick Y. Wen

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.

Original languageEnglish (US)
Pages (from-to)180-188
Number of pages9
JournalNeuro-oncology
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2015

Keywords

  • adaptive randomization
  • biomarkers
  • clinical trials
  • glioblastoma

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group'. Together they form a unique fingerprint.

Cite this